News

For Scleroderma Patients with PH, phaware365 App Is Welcome Way to Share

The nonprofit association phaware is dedicated to raising global awareness of a common complication in patients with scleroderma, the chronic lung disease known as pulmonary hypertension (PH). phaware connects with innovative technologies and industry leaders to find new paths to a PH cure and, from one of these collaborations, comes a new mobile app allowing users…

Mycophenolate Mofitil Identified As Promising Scleroderma-Related Interstitial Lung Disease Treatment

New data recently presented at the 2015 American College of Rheumatology Annual Meeting in San Francisco showed that mycophenolate mofitil is as efficient as cyclophosphamide for the treatment of interstitial lung disease in individuals with scleroderma. Scleroderma, or systemic sclerosis, is a chronic systemic autoimmune disease characterized by a…

Scleroderma Testimonials

What is it like living with scleroderma? This video takes a look at some of the struggles that patients face when dealing with this life altering autoimmune disease. The video features actor, Jason Alexander; Football Hall of Famer, Barry Sanders; Actor and Comedian, Mark Teich; Author and Personality,…

iBio Receives Patent for Key Fibrotic Therapeutics Platform

iBio, Inc., a plant-based biotechnology company focused on developing biological therapies for several fibrotic diseases including idiopathic pulmonary fibrosis and systemic sclerosis, recently announced it has received a notification from the European Patent Office stating that the opposition period for the iBio patent 2192172, entitled “System for Expression of…

Reata Reports New PAH Therapy in Phase 2 Trial Shows Promise

Reata Pharmaceuticals, Inc., a biopharmaceutical company based in Irving, Texas, recently announced positive data from the Phase 2 clinical trial LARIAT assessing the company’s candidate product bardoxolone methyl for pulmonary arterial hypertension (PAH). The results were recently presented by Dr. Ronald Oudiz, Director of the Pulmonary Hypertension Center and…